Annual Reports in Medicinal Chemistry

<ol> <li>Challenges in Drug Discovery at Schering-Plough Research Institute: A Personal Reflection</li> <p> <li>My Perspective on Time, Managers—and Scientific Fun</li> <p> <li>A Career in Medicinal Chemistry - A Journey in Drug Discovery</li> <p> <li>Selective Inhibitors of PDE2, PDE9 and PDE10 - Modulators of Activity of the Central Nervous System</li> <p> <li>Beyond Secretases: Kinases Inhibitors for the Treatment of Alzheimer’s Disease </li> <p> <li>Orexin Receptor Antagonists in Development for Insomnia and CNS Disorders</li> <p> <li>Discovery and Development of Prolylcarboxypeptidase (PRCP) Inhibitors for Cardiometabolic Disorders</li> <p> <li>Molecular Targeting of Imaging and Drug Delivery Probes in Atherosclerosis </li> <p> <li>Oral GLP-1 Modulators for the Treatment of Diabetes</li> <p> <li>Recent Advances in the Discovery and Development of CCR1 Antagonists</li> <p> <li>Emerging Targets for the Treatment of Idiopathic Pulmonary Fibrosis</li> <p> <li>Targeting the Nuclear Hormone Receptor RORgt for the Treatment of Autoimmune and Inflammatory Disorders</li> <p> <li>Recent Advances in Small-Molecule Modulation of Epigenetic Targets: Discovery and Development of Histone Methyltransferase- and Bromodomain Inhibitors</li> <p> <li>Inhibition of Ubiquitin Proteasome System Enzymes for Anticancer Therapy</li> <p> <li>Targeting Protein–Protein Interactions to Treat Cancer―Recent Progress and Future Directions</li> <p> <li>Recent Progress in the Discovery of Neuraminidase Inhibitors as Anti-influenza Agents</li> <p> <li>Novel Therapeutics in Discovery and Development for Treatment of Chronic HBV Infection</li> <p> <li>Special Challenges to the Rational Design of Antibacterial Agents</li> <p> <li>Recent Advances in Small Molecule Target Identification Methods</li> <p> <li>Neuroinflammation in Mood Disorders: Mechanisms and Drug Targets</li> <p> <li>Inhibitors of hERG Channel Trafficking—A Cryptic Mechanism For QT Prolongation</li> <p> <li>Recent Progress in Small-Molecule Agents Against Age-Related Macular Degeneration</li> <p> <li>Synthetic Macrocycles in Small-Molecule Drug Discovery</li> <p> <li>Glossary of Terms Used in Medicinal Chemistry Part II (IUPAC Recommendations 2011)</li> <p> <li>Case History: Xalkori^TM (Crizotinib), a Potent and Selective Dual Inhibitor of MET and ALK for Cancer Treatment</li> <p> <li>Case History: Vemurafenib, a Potent, Selective, and First-in-Class Inhibitor of Mutant BRAF for the Treatment of Metastatic Melanoma</li> <p> <li>New Chemical Entities Entering Phase III Trials in 2012 28. To Market, to Market—2012</li></ol>